{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:36:57Z","timestamp":1792147017799,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1007\/s11864-005-0003-4","type":"journal-article","created":{"date-parts":[[2007,7,26]],"date-time":"2007-07-26T08:55:05Z","timestamp":1185440105000},"page":"197-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prolymphocytic leukemia"],"prefix":"10.1007","volume":"6","author":[{"given":"Ahmed","family":"Absi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"3_CR1","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","volume":"78","author":"E Matutes","year":"1991","unstructured":"Matutes E, Brito-Babapulle V, Swansbury J, et al.: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991, 78:3269\u20133274. This case series is one of the largest for T-PLL and provides a useful overview of the usual clinical manifestations and prognosis of T-PLL.","journal-title":"Blood"},{"key":"3_CR2","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/sj.leu.2400725","volume":"11","author":"R Pawson","year":"1997","unstructured":"Pawson R, Schulz TF, Matutes E, et al.: The human T-cell lymphotropic viruses types I\/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukemia 1997, 11:1305\u20131311.","journal-title":"Leukemia"},{"key":"3_CR3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1046\/j.1365-2141.1997.9702605.x","volume":"96","author":"V Brito-Babapulle","year":"1997","unstructured":"Brito-Babapulle V, Maljaie SH, Matutes E, et al.: Relationship of T leukaemias with cerebriform nuclei to T-prolymphocytic leukaemia: a cytogenetic analysis with in situ hybridization. Br J of Haematol 1997, 96:724\u2013732.","journal-title":"Br J of Haematol"},{"key":"3_CR4","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW: Pathology and Genetics of Tumours of Haematopoietic and Lympkoid Tissues. World Health Organization Classification of Tumours; IARC Press, 2001."},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","volume":"22","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De Martinis M, Matutes E, et al.: Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998, 22:185\u2013191.","journal-title":"Leuk Res"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1073\/pnas.95.7.3885","volume":"95","author":"L Virgilio","year":"1998","unstructured":"Virgilio L, Lazzeri C, Bichi R, et al.: Deregulated expression of TCL1 causes T-cell leukemia in mice. Proc Natl Acad Sci 1998, 95:3885\u20133889.","journal-title":"Proc Natl Acad Sci"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1073\/pnas.96.6.2949","volume":"96","author":"Y Pekarsky","year":"1999","unstructured":"Pekarsky Y, Hallas C, Isobe M, et al.: Abnormalities at 14q32.1 in T-cell malignancies involve two oncogenes. Proc Natl Acad Sci 1999, 96:2949\u20132951.","journal-title":"Proc Natl Acad Sci"},{"key":"3_CR8","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/nm1097-1155","volume":"3","author":"S Stilgenbauer","year":"1997","unstructured":"Stilgenbauer S, Schaffner C, Litterst A, et al.: Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 1997, 3:1155\u20131159.","journal-title":"Nat Med"},{"key":"3_CR9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/10428199909093739","volume":"33","author":"L Shvidel","year":"1999","unstructured":"Shvidel L, Shtalrid M, Bassous L, et al.: B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors, and evidence for a group with an indolent course. Leuk Lymphoma 1999, 33:169\u2013179. This case series, along with the one reported by Hercher et al. [10 ], establishes the usual clinical manifestation, diversity, and prognosis of B-PLL.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"3_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3109\/10428190109097717","volume":"42","author":"C Hercher","year":"2001","unstructured":"Hercher C, Robain M, Davi F, et al.: A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma 2001. 42(5): pp. 981\u2013987. This case series, along with the one reported by Shvidel et al. [9 ], establishes the usual clinical manifestation, diversity, and prognosis of B-PLL.","journal-title":"Leuk Lymphoma"},{"key":"3_CR11","first-page":"1640","volume":"8","author":"E Matutes","year":"1994","unstructured":"Matutes E, Owusu-Ankomah K, Morilla R, et al.: The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994, 8:1640\u20131645.","journal-title":"Leukemia"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1309\/PPK0-TJUK-1UAR-3194","volume":"115","author":"E Schlette","year":"2001","unstructured":"Schlette E, Bueso-Ramos C, Giles F, et al.: Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol 2001, 115:571\u2013581.","journal-title":"Am J Clin Pathol"},{"key":"3_CR13","first-page":"27","volume":"1","author":"V Brito-Babapulle","year":"1987","unstructured":"Brito-Babapulle V, Pittman S, Melo JV, et al.: Cytogenetic studies on prolymphocytic leukemia. B-cell prolymphocytic leukemia. Hem Pathol 1987, 1:27\u201333.","journal-title":"Hem Pathol"},{"key":"3_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-4608(91)90228-M","volume":"55","author":"V Brito-Babapulle","year":"1991","unstructured":"Brito-Babapulle V, Catovsky D, et al.: Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 1991, 55:1\u20139.","journal-title":"Cancer Genet Cytogenet"},{"key":"3_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1365-2141.1996.457995.x","volume":"93","author":"KF Wong","year":"1996","unstructured":"Wong KF, Chan JK, Sin VC, et al.: T-cell form of chronic lymphocytic leukaemia: a reaffirmation of its existence. Br J Haematol 1996, 93:157\u2013159.","journal-title":"Br J Haematol"},{"key":"3_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.10398","volume":"74","author":"F Cavazzini","year":"2003","unstructured":"Cavazzini F, Cuneo A, Bardi A, et al.: Indolent T-cell prolymphocytic leukemia: a case report and a review of the literature. Am J Hematol 2003, 74:145\u2013147.","journal-title":"Am J Hematol"},{"key":"3_CR17","first-page":"580","volume":"94","author":"D Catovsky","year":"1996","unstructured":"Catovsky D, Matutes E, Brito-Babapulle V, et al.: Is T-cell CLL a disease entity? Br J Haematol 1996, 94:580.","journal-title":"Br J Haematol"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1046\/j.1365-2141.1998.00977.x","volume":"103","author":"R Garand","year":"1998","unstructured":"Garand R, Goasguen J, Brizard A, et al.: Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Br J Haematol 1998, 103:488\u2013494.","journal-title":"Br J Haematol"},{"key":"3_CR19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-4615-3086-2_6","volume":"64","author":"LE Robertson","year":"1993","unstructured":"Robertson LE, Keating MJ, et al.: Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions. Cancer Treat Res 1993, 64:105\u2013119.","journal-title":"Cancer Treat Res"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1995.13.3.570","volume":"13","author":"A Saven","year":"1995","unstructured":"Saven A, Lemon RH, Kosty M, et al.: 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995, 13:570\u2013574.","journal-title":"J Clin Oncol"},{"key":"3_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1600-0609.1997.tb01409.x","volume":"58","author":"D Rondelli","year":"1997","unstructured":"Rondelli D, Lauria F, Zinzani PL, et al.: 2-Chlorodeoxyadenosine in the treatment of relapsed\/refractory chronic lymphoproliferative disorders. Eur J Haematol 1997, 58:46\u201350.","journal-title":"Eur J Haematol"},{"key":"3_CR22","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/JCO.1992.10.11.1821","volume":"10","author":"K Barton","year":"1992","unstructured":"Barton K, Larson RA, O\u2019Brien S, et al.: Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine. J Clin Oncol 1992, 10:1821.","journal-title":"J Clin Oncol"},{"key":"3_CR23","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1200\/JCO.1995.13.5.1284","volume":"13","author":"L Palomera","year":"1995","unstructured":"Palomera L, Domingo JM, Agullo JA, et al.: Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine. J Clin Oncol 1995, 13:1284\u20131285.","journal-title":"J Clin Oncol"},{"key":"3_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s002770050368","volume":"76","author":"I Lorand-Metze","year":"1998","unstructured":"Lorand-Metze I, Oliveira GB, Aranha FJ: Treatment of prolymphocytic leukemia with cladribine. Ann Hematol 1998, 76:85\u201386.","journal-title":"Ann Hematol"},{"key":"3_CR25","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","volume":"12","author":"J Mercieca","year":"1994","unstructured":"Mercieca J, Matutes E, Dearden C, et al.: The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994, 12:2588\u20132593.","journal-title":"J Clin Oncol"},{"key":"3_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1600-0609.1996.tb01935.x","volume":"56","author":"E Van Den Neste","year":"1996","unstructured":"Van Den Neste E, Delannoy A, Vandercam B, et al.:Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996, 56:235\u2013240.","journal-title":"Eur J Haematol"},{"key":"3_CR27","doi-asserted-by":"publisher","first-page":"6088","DOI":"10.1074\/jbc.270.11.6088","volume":"270","author":"A Treumann","year":"1995","unstructured":"Treumann A, Lifely MR, Schneider P, et al.: Primary structure of CD52. J Biol Chemist 1995, 270:6088\u20136099.","journal-title":"J Biol Chemist"},{"key":"3_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x","volume":"96","author":"AL Bowen","year":"1997","unstructured":"Bowen AL, Zomas A, Emmett E, et al.: Subcutaneous Campath-1H in fludarabine-resistant\/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997, 96:617\u2013619.","journal-title":"Br J Haematol"},{"key":"3_CR29","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.1997.15.7.2667","volume":"15","author":"R Pawson","year":"1997","unstructured":"Pawson R, Dyer MJ, Barge R, et al.: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997, 15:2667\u20132672. This study is the first large phase II study conducted by the European collaborative group investigating alemtuzumab in 15 patients with T-PLL who had either progressive or refractory disease despite previous treatment, and compared the results with a matched group of patients who received pentostatin.","journal-title":"J Clin Oncol"},{"key":"3_CR30","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","volume":"98","author":"CE Dearden","year":"2001","unstructured":"Dearden CE, Matutes E, Cazin B, et al.: High-remission rate in T-cell prolymphocytic leukemia with Campath-1H. Blood, 2001, 98:1721\u20131726. This study reported the results of 39 patients with relapsed\/ refractory T-PLL who received alemtuzumab, some of whom had received a subsequent SCT.","journal-title":"Blood"},{"key":"3_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.20.1.205","volume":"20","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Cazin B, Coutre S, et al.: Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002, 20:205\u2013213. This is the largest study for using alemtuzumab in relapsed\/ refractory T-PLL that established the role of alemtuzumab in T-PLL.","journal-title":"J Clin Oncol"},{"key":"3_CR32","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, et al.: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990\u20134997.","journal-title":"Blood"},{"key":"3_CR33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjorkholm M, et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768\u2013773.","journal-title":"Blood"},{"key":"3_CR34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3816\/CLM.2004.n.002","volume":"4","author":"M Keating","year":"2004","unstructured":"Keating M, Coutre S, Rai K, et al.: Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004, 4:220\u2013227. This is an important review for the guidelines of using alemtuzumab in CLL, the same applied when used for T-PLL.","journal-title":"Clin Lymphoma"},{"key":"3_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3816\/CLM.2002.n.016","volume":"3","author":"DD Nguyen","year":"2002","unstructured":"Nguyen DD, Cao TM, Dugan K, et al.: Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002, 3:105\u2013110.","journal-title":"Clin Lymphoma"},{"key":"3_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1600-0609.1992.tb00912.x","volume":"49","author":"MC Aggio","year":"1992","unstructured":"Aggio MC: Splenic irradiation as initial therapy for prolymphocytic leukemia. Eur J Haematol 1992, 49:46\u201347.","journal-title":"Eur J Haematol"},{"key":"3_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/jjco\/28.4.267","volume":"28","author":"K Yamamoto","year":"1998","unstructured":"Yamamoto K, Hamaguchi H, Nagata K, et al.: Splenic irradiation for prolymphocytic leukemia: is it preferable as an initial treatment or not? Jap J Clin Oncol 1998, 28:267\u2013269.","journal-title":"Jap J Clin Oncol"},{"key":"3_CR38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.1997.15.1.37","volume":"15","author":"A Saven","year":"1997","unstructured":"Saven A, Lee T, Schlutz M, et al.: Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J Clin Oncol 1997, 15:37\u201343.","journal-title":"J Clin Oncol"},{"key":"3_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/cncr.11000","volume":"97","author":"M Montillo","year":"2003","unstructured":"Montillo M, Tedeschi A, O\u2019Brien S, et al.: Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003, 97:114\u2013120.","journal-title":"Cancer"},{"key":"3_CR40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.1991.9.1.175","volume":"9","author":"HG Chun","year":"1991","unstructured":"Chun HG, Leyland-Jones B, Cheson BD: Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991, 9:175\u2013188.","journal-title":"J Clin Oncol"},{"issue":"Suppl8","key":"3_CR41","first-page":"66","volume":"17","author":"HM Kantarjian","year":"1990","unstructured":"Kantarjian HM, Redman JR, Keating MJ: Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol 1990, 17(Suppl8):66\u201370.","journal-title":"Semin Oncol"},{"key":"3_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/ajh.2830400117","volume":"40","author":"P Marlton","year":"1992","unstructured":"Marlton P, McCarthy C, Taylor K: Fludarabine-induced cytogenetic remission in prolymphocytic leukemia. Am J Hematol 1992, 40:71\u201372.","journal-title":"Am J Hematol"},{"key":"3_CR43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chinn PC, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435\u2013445.","journal-title":"Blood"},{"key":"3_CR44","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: 50% of patients respond to a four dose treatment program. J Clin Oncol 1998, 16:2825\u20132833.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"3_CR45","first-page":"S15","volume":"12","author":"MS Czuczman","year":"2001","unstructured":"Czuczman MS: Combination chemotherapy and rituximab. Anti-Cancer Drugs 2001, 12(Suppl 2):S15-S19.","journal-title":"Anti-Cancer Drugs"},{"key":"3_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00277-003-0805-z","volume":"83","author":"YA Mourad","year":"2004","unstructured":"Mourad YA, Taher A, Chehal A, et al.: Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. Ann Hematol 2004, 83:319\u2013321.","journal-title":"Ann Hematol"},{"key":"3_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000040977","volume":"102","author":"G Vartholomatos","year":"1999","unstructured":"Vartholomatos G, Tsiara S, Christou L, et al.: Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia. Acta Haematol 1999, 102:94\u201398.","journal-title":"Acta Haematol"},{"key":"3_CR48","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/10428190210178","volume":"43","author":"J Perz","year":"2002","unstructured":"Perz J, Topaly J, Fruehauf S, et al.: Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2002, 43:149\u2013151.","journal-title":"Leuk Lymphoma"},{"key":"3_CR49","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/(SICI)1096-8652(200004)63:4<230::AID-AJH13>3.0.CO;2-2","volume":"63","author":"L Shvidel","year":"2000","unstructured":"Shvidel L, Shtalrid M, Klepfish A, et al.: Successful autologous stem cell transplantation in aggressive prolymphocytic leukemia. Am J Hematol 2000, 63:230\u2013231.","journal-title":"Am J Hematol"},{"key":"3_CR50","first-page":"371","volume":"17","author":"J Mehta","year":"1996","unstructured":"Mehta J, Powles R, Singhal S, et al.: Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versushost disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996, 17:371\u2013375.","journal-title":"Bone Marrow Transplant"},{"key":"3_CR51","first-page":"3555","volume":"9","author":"AE Frankel","year":"2003","unstructured":"Frankel AE, Fleming DR, Hall PD, et al.: A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 2003, 9:3555\u20133561.","journal-title":"Clin Cancer Res"},{"key":"3_CR52","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","volume":"19","author":"E Olsen","year":"2001","unstructured":"Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001, 19:376\u2013388.","journal-title":"J Clin Oncol"},{"key":"3_CR53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10147-003-0349-1","volume":"8","author":"K Murase","year":"2003","unstructured":"Murase K, Matsunaga T, Sato T, et al.: Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement. Int J Clin Oncol 2003, 8:391\u2013394.","journal-title":"Int J Clin Oncol"},{"key":"3_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1034\/j.1600-0609.2001.00377.x","volume":"66","author":"L Garderet","year":"2001","unstructured":"Garderet L, Bittencourt H, Kaliski A, et al.: Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation. Eur J Haematol 2001, 66:137\u2013139.","journal-title":"Eur J Haematol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-005-0003-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-005-0003-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-005-0003-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-005-0003-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:35:34Z","timestamp":1659090934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-005-0003-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1007\/s11864-005-0003-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}